Biogen Idec

Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015

Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…

Oral Disease Modifying Agents for Multiple Sclerosis Are Now More Preferred by Neurologists

A survey of 97 neurologists conducted in June 2015 revealed specialists within the field of neurologyĀ are increasingly avoiding prescribing injectables to patients suffering from multiple sclerosis, as orally-available disease modifying-agents (DMAs) continue to gain in popularity. The survey was conducted and reported by Spherix Global Insights, a newly established business…

NHS Wales Approves Biogen’s Plegridy for Relapsing Remitting MS

Relapsing remitting multiple sclerosis (RRMS) treatment PlegridyĀ (peg interferon beta-1a) by Biogen Idec, has just received Welsh NHS approval, which should make it available to patients by late October 2015. The decisionĀ follows NHS Scotland’s approval earlier this year, however, theĀ biweekly interferon beta shot has yet to be madeĀ available in England’s NICE…

Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference

Biogen plans toĀ present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 ā€“ 25, 2015, including numerous presentations focusing on multiple sclerosis. Ā In a company press release, Biogen statedĀ ā€œAt AAN, we will feature new scientific data, including research highlighting the…

A Step Toward Multiple Sclerosis Treatment? Phase 2 ANTI-LINGO-1 Results Announced

Biogen Idec, a Cambridge Massachusetts Biotechnology company,Ā has released results from itsĀ Phase 2 acute optic neuritis (AON) RENEW trial. The trial testedĀ anti-LINGO-1, a medication that restores myelin — a fatty substance that facilitates nerve cell impulses by wrapping around them and providing insulation. The trial results indicateĀ that anti-LINGO-1…

MS Blueprint Online Program by Biogen Helps Patients Live Happier

Cambridge, Massachusetts-basedĀ Biogen IdecĀ has just announced a new support program for people living with multiple sclerosis (MS) that encourages patients to turn their attention to daily activities that enhance their emotional and mental state. The newly launched MS Blueprint program assists patients and caregivers in setting positive and realistic goals,…

Large Multiple Sclerosis Product Update To Be Presented By Biogen

Biogen Idec, one of the first true biotech companies specializing in products indicated forĀ neurodegenerative diseases, hematologic conditions, and autoimmune disorders, is preparing to present over 90 poster presentations during this week’s 6th Joint ACTRIMS-ECTRIMS Meeting. The event is scheduled to take place from Wednesday, September 10th through Saturday the…

New Multiple Sclerosis Drug May Repair Nerve Demyelination

As researchers continue to develop a clearer understanding of the underlying causes ofĀ multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…

Natalizumab, Other Biogen Idec MS Therapies Featured at Medical Congresses; Company Joins Sailing Sclerosis Foundation Oceans of Hope Project

Biogen Idec, a U.S. biotechnology company specializing in therapies for neurological disorders, autoimmune disorders and cancer, has announced that more than 60 company-sponsored presentations highlighting key data from its extensive portfolio of marketed and investigational multiple sclerosis (MS) therapies were featured during two 2014 neurology conferences. The company…

Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis. The…

Committee for Medicinal Products for Human Use Adopts Positive Opinion For Plegridy As a Treatment for MS In The European Union

TheĀ CommitteeĀ for Medicinal Products for Human UseĀ (CHMP) of the European Medicines AgencyĀ recently offered a positive opinion for the marketing authorization of Biogen Idec’s Plegridy therapy, a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The positive opinion will now be sent to the European Commission, which grants…